{"id":"NCT03248037","sponsor":"Cornea Research Foundation of America","briefTitle":"Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation","officialTitle":"Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-05","primaryCompletion":"2019-07-09","completion":"2019-07-09","firstPosted":"2017-08-14","resultsPosted":"2021-02-12","lastUpdate":"2021-02-12"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Fuchs' Endothelial Dystrophy","Bullous Keratopathy"],"interventions":[{"type":"DRUG","name":"Netarsudil","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Netarsudil","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.","primaryOutcome":{"measure":"Intraocular Pressure","timeFrame":"from date of randomization until the date of first documented intraocular pressure elevation exceeding defined threshold up to 9 months","effectByArm":[{"arm":"Netarsudil","deltaMin":11,"sd":null},{"arm":"Placebo","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["27666015","19643499","33045216"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":95},"commonTop":["Air re-injection","Ocular irritation considered related to study drug use"]}}